Pfizer Inc. cemented a deal first announced in March to sell its antiviral medication Paxlovid in China through a state-owned company, adding to supply of Covid treatments in the country that’s now facing a massive infection surge.
China Meheco Group Co. signed an agreement Wednesday with Pfizerto import and distribute Paxlovid on the mainland, the company said in a filing with the Shanghai Stocks Exchange. The agreement is effective immediately and expires on Nov. 30, 2023, the statement said. Further terms weren’t disclosed.
Pfizer’s relationship with Meheco has been in place for some time, with a contract signed earlier ...
